Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21906462 | 0.90 | NLRP3 (0.80) | NLRP3 | |
| SCHEMBL21906460 | 0.89 | NLRP3 (0.79) | NLRP3 | |
| SCHEMBL21971211 | 0.85 | NLRP3 (1.00) | NLRP3 | |
| SCHEMBL21906430 | 0.85 | NLRP3 (1.00) | NLRP3GSTO1 | |
| SCHEMBL21906443 | 0.83 | NLRP3 (0.80) | NLRP3 | |
| SCHEMBL21906456 | 0.83 | NLRP3 (1.00) | NLRP3 | |
| SCHEMBL21906431 | 0.83 | NLRP3 (0.80) | NLRP3 | |
| SCHEMBL21906441 | 0.83 | NLRP3 (1.00) | NLRP3 | |
| SCHEMBL21970694 | 0.83 | NLRP3 (1.00) | NLRP3 | |
| SCHEMBL21971213 | 0.83 | NLRP3 (0.76) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236045-B2 | Substituted sulfoximine compounds | CADILA HEALTHCARE LIMITED (IN) | 2022-02-01 | — | — | US | claimed |
| US-20200140382-A1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2020-05-07 | — | — | US | claimed |
| EP-3634951-B1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS | ZYDUS LIFESCIENCES LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| EP-3634951-B1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS | ZYDUS LIFESCIENCES LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-11236045-B2 | Substituted sulfoximine compounds | CADILA HEALTHCARE LIMITED (IN) | 2022-02-01 | — | — | US | disclosed |
| US-11236045-B2 | Substituted sulfoximine compounds | CADILA HEALTHCARE LIMITED (IN) | 2022-02-01 | — | — | US | disclosed |
| EP-3914585-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020154499-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200140382-A1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2020-05-07 | — | — | US | disclosed |
| US-20200140382-A1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885GSTO1 3612/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885GSTO1 4681/4885 |
| US-20200140382-A1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS | IL18, NLRP3, NOD1 | NLRP3 2/4885GSTO1 1377/4885 |
| US-11236045-B2 | Substituted sulfoximine compounds | IL18, NLRP3, NOD1 | NLRP3 2/4885GSTO1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.